Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 8/20 | 0.40 |
| ▸ | TP53 | P04637 | 6/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14697372 | 0.89 | MAPT (0.36) | MAPT | |
| SCHEMBL14697410 | 0.89 | CYP2C9 (0.45) | ALOX5 | |
| SCHEMBL14698024 | 0.85 | ALOX5 (0.51) | ALOX5MEN1KMT2APRNPMAPT | |
| SCHEMBL2295394 | 0.84 | ALOX5 (0.52) | ALOX5MEN1KMT2APRNPMAPT | |
| SCHEMBL14697666 | 0.83 | CYP2C9 (0.52) | — | |
| SCHEMBL14697648 | 0.82 | ALOX5 (0.45) | ALOX5MEN1KMT2APRNPMAPT | |
| SCHEMBL14697949 | 0.81 | ALOX5 (0.48) | ALOX5MEN1KMT2APRNPMAPT | |
| SCHEMBL14697743 | 0.80 | CYP2C9 (0.47) | ALOX5MAPT | |
| SCHEMBL14697677 | 0.80 | CYP2C9 (0.45) | ALOX5 | |
| SCHEMBL14697713 | 0.80 | CYP2C9 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744342-B1 | THERAPEUTIC METHODS | GLAXOSMITHKLINE LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10238678-B2 | Therapeutic methods | GLAXOSMITHKLINE LLC (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3199531-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| US-9682999-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20150320777-A1 | Therapeutic Methods | GLAXOSMITHKLINE LLC | 2015-11-12 | — | — | US | disclosed |
| US-9119868-B2 | Therapeutic methods | GLAXOSMITHKLINE LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2015-03-19 | — | — | US | disclosed |
| US-8927593-B2 | Benzofuran compounds for the treatment of hepatitis C virus infections | GLAXO GROUP LIMITED (GB) | 2015-01-06 | — | — | US | disclosed |
| US-20140212384-A1 | Therapeutic Methods | GLAXOSMITHKLINE LLC | 2014-07-31 | — | — | US | disclosed |
| EP-2744342-A1 | THERAPEUTIC METHODS | GlaxoSmithKline LLC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2744332-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | GLAXO GROUP LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| WO-2013028371-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | GLAXO GROUP LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013025992-A1 | THERAPEUTIC METHODS | GLAXOSMITHKLINE LLC (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237501-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | ALOX5 1161/4885MEN1 4450/4885KMT2A 3110/4885 |
| US-20150320777-A1 | Therapeutic Methods | HAVCR2, SLC10A1, OAT | ALOX5 1534/4885MEN1 4207/4885KMT2A 4626/4885 |
| US-20150080343-A1 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | UGT1A1, CYP3A43, ZC3HAV1 | ALOX5 1161/4885MEN1 4450/4885KMT2A 3110/4885 |
| US-10238678-B2 | Therapeutic methods | HAVCR2, SLC10A1, OAT | ALOX5 1534/4885MEN1 4207/4885KMT2A 4626/4885 |
| US-20140212384-A1 | Therapeutic Methods | HAVCR2, SLC10A1, OAT | ALOX5 1534/4885MEN1 4207/4885KMT2A 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.